MedTrace Logo

Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes

NCT06129526 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2023-11-15

No results posted yet for this study

Summary

Investigation of the efficacy and safety of an Eicosapentaenoic acid (EPA) supplement versus a placebo supplement on plasma triglyceride levels as well as inflammatory, thrombotic, endothelial and platelet activation markers, in patients with type-2 diabetes mellitus (DM-2).

Conditions

Interventions

DIETARY_SUPPLEMENT

EPAVasc

EPAVasc: 1,875mg EPA / 125mg DHA / 3.75μg Vitamin D / 12mg tocopherol

DIETARY_SUPPLEMENT

Corn Oil

Corn Oil

Sponsors & Collaborators

  • LIBYTEC Pharmaceutical S.A.

    collaborator UNKNOWN

  • University of Ioannina

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-31
Primary Completion
2024-09-30
Completion
2024-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06129526 on ClinicalTrials.gov